Emotional and Behavioral Disorders in Children and Adolescents

Summary

The emotional and behavioral disorder drug market is changing as a result of the heightened awareness of these diseases in young children and adolescents and the use of drugs dedicated to controlling these problems. The key objective now is safe use and correct diagnosis. The drugs previously used had many side effects, the principal one being suicidal tendencies. Now the market is moving towards drugs that are safer to use. However, much remains to be done.

Many companies are doing research on drugs with fewer side effects and by the end of the decade, it is expected that more of them will be on the market. Efforts are underway to perform clinical trials to prove the safety of these drugs for children. These currently still are considered as "off label" uses.

Available alternatives and preferences for various drugs have made the industry acutely aware of related issues and economic characteristics. This timely BCC study looks at almost all the drug markets affected by these factors. It discusses the strengths and weaknesses of drugs being used for children, and whose safety still has not been established by regulatory authorities. Also examined are the demographics of drug use as divided by preschoolers and other age groups. In addition, the report looks at worldwide sales by region.

Scope Of Study

The report contains:

• An overview of the behavioral and emotional disorders in children and adolescents
• Sales figures for the following categories of drugs: benzodiazepines, mood stabilizers, antipsychotics, SSRIs, tricyclic antidepressants, CNS stimulants and nonstimulants
• Market projections on their worldwide use to 2010
• Drug categorizations by disorder with sales figures for each
• Profiles of the companies selling these products
• Discussion of factors affecting markets as a result of regulatory issues.

Report Highlights

• The world market for drugs to treat mental, emotional and behavioral problems in children and adolescents is estimated at $13.4 billion in 2005 and is expected to rise at an average annual growth rate (AAGR) of 7.2% to $19 billion in 2010.
• Antianxiety drugs and antidepressants currently represent the largest market, but will rise at an AAGR of only 5.5% through the period.
• Drugs for bipolar, autistic, eating disorders and schizophrenia will fare somewhat better, rising at an AAGR of 5.8% to $4.1 billion in 2010.
• The category that includes ADHD and conduct and learning disorders will rise the fastest at an AAGR of 9.7% to become the largest segment in 2010 at $8.1 billion.

Contents

• Introduction
  • Study Objectives
  • Reasons For Doing This Study
  • Contributions Of The Study
  • Scope Of The Study
  • Methodology
  • Information Sources
  • About The Author
  • Related BCC Reports
  • BCC Online Services
  • Disclaimer
• Summary
  • Summary Table: Worldwide Sales Of Drugs Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Summary Figure: Worldwide Sales Of Drugs Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
• Overview
  • Definitions Of Emotional And/Or Behavior Disorders
  • Terminology
  • Classification Of Emotional And Behavioral Disorders
• Causes Of Emotional And Behavior Disorders
  • Biological Factors
    • Psychophysiological And Genetic Influences
    • Neurological Dysregulation
  • Environmental Factors
    • School-Related Factors
    • Parent Psychological Factors
    • Familial Contributions
      • Divorce, Marital Distress And Violence
      • Family Adversity And Insularity
      • Parent-Child Interactions
      • Other Family Characteristics
  • Characteristics Of Students With Behavior Disorders
    • Intelligence And Achievement
      • Social Skills And Interpersonal Relationships
      • Antisocial Behavior
      • Withdrawn Behavior
    • Manifestations Of Behavior Disorders
• Types Of Disorders
  • Anxiety Disorders
    • Types Of Anxiety Disorders
    • Causes
    • Symptoms And Treatment
      • Psychological Treatments
      • Psychopharmacological Treatments
      • Environmental Treatments
  • Severe Depression
    • Causes
    • Symptoms And Treatment
  • Bipolar Disorder
    • Symptoms And Treatment
  • Attention Deficit Hyperactivity Disorder
    • Symptoms And Treatment
  • Autism
    • Symptoms And Treatment
  • Schizophrenia
    • Symptoms And Treatment
  • Learning Disorders
    • Symptoms And Treatment
    • Causes
  • Conduct Disorder
    • Symptoms And Treatment
  • Eating Disorders
    • Symptoms And Treatments
• Drug Classification
  • Classification Based On Mechanism Of Action
    • Benzodiazepines
    • Selective Serotonin Reuptake Inhibitors (SSRIS)
    • Tricyclic Antidepressants
    • Antihistamines
    • Major Tranquilizers Or Neuroleptics
    • Mood Stabilizers
    • Cns Stimulants
    • Nonstimulants
    • Atypical Antipsychotics
  • Classification Based On Therapeutic Category
    • Antianxiety Drugs
      • Clorazepate
      • Chlordiazepoxide
      • Chlorpromazine
      • Clonezepam
      • Diazepam
      • Doxipine
      • Fluoxetine Hydrochloride
      • Fluphenazine
      • Fluvoxamine Maleate
      • Haloperidol
      • Hydroxyzine
      • Nortriptyline
      • Oxazepam
      • Sertraline Hydrochloride
      • Thioridazine
      • Thioxanthene
      • Trifluperazine
    • Severe Depression Drugs
      • Amitryptyline
      • Fluoxetine Hydrochloride
      • Impramine
      • Sertraline Hydrochloride
    • Bipolar Disorder Drugs
      • Lithium
      • Divalproex
      • Carbamazepine
    • Attention Deficit Hyperactivity Disorder (ADHD) Drugs
      • Amphetamines
      • Dextroamphetamine
      • Methylphenidate
      • Pemoline
      • Atomoxetine Hydrochloride
    • Autistic Disorder Drugs
      • Risperidone
    • Schizophrenia Drugs
• Safety, Efficacy And Regulation
  • Safety And Efficacy
  • Regulatory Aspects
    • Drug Approvals
• Industry Structure
  • Behavior And Emotional Disorder Drug Industry Market By Company
    • Antianxiety
      • Antidepressants
      • Bipolar Disorders
      • Adhd Disorders
      • Autistic Disorders
      • Schizophrenia
      • Learning Disorders
      • Eating Disorders
      • Conduct Disorders
• Market By Drug Types
  • Total Market Size
  • Sales By Type Of Therapeutic Category
    • Benzodiazepines
    • Selective Serotonin Reuptake Inhibitors (SSRIS)
    • Tricyclic Antidepressants
    • Antihistamines
    • Major Tranquilizers, Neuroleptics Or Antipsychotics
    • Mood Stabilizers
    • Cns Stimulants
    • Nonstimulants
    • Atypical Antipsychotics
• Market By Disorders
  • Total Market Size
  • Sales By Type Of Drugs
    • Antianxiety Agents
    • Drugs Used To Treat Depression
    • Drugs Used To Treat Bipolar Disorder
    • Adhd Drugs
    • Autistic Disorder Drugs
    • Schizophrenia Drugs
    • Drugs For Learning Disorders
    • Drugs For Eating Disorders
    • Conduct Disorder Drugs
• Demographics
• Overview
  • Antianxiety Agents
  • Antidepressants
  • Bipolar Disorder Drugs
  • Adhd Drugs
  • Autistic Disorder Drugs
  • Schizophrenia Drugs
  • Learning Disorder Drugs
  • Eating Disorder Drugs
  • Conduct Disorder Drugs
• New Developments
  • Astrazeneca
  • Bristol-Myers Squibb
  • Celgene
  • Glaxosmithkline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanolfi-Aventis
  • Shire
  • Solvay
  • Wyeth
• Patents
  • Patents By Year
  • Patents By Category
  • Significant Patents Of 2005
  • Patents By Company
  • Patents By Country
  • Patents By Assignee
• International Aspects
  • Total Market Size
  • Regional Sales By Type Of Disorder
    • Antianxiety Agents
    • Antidepressants
    • Bipolar Disorder Drugs
    • Adhd Drugs
    • Autistic Disorder Drugs
    • Schizophrenia Drugs
      • Learning Disorder Drugs
      • Conduct Disorder Drugs
      • Eating Disorder Drugs
  • Prevelance Of Emotional And Behavioral Disorders In Children And Adolescents In Selected Countries
    • United States
    • United Kingdom
    • India
    • China
• Company Profiles
  • Abbott Laboratories
  • Alliant Pharmaceuticals
  • Bristol-Myers Squibb
  • Celegene
  • Celltech Pharmaceuticals
  • Eli Lilly
  • Glaxosmithkline Plc
  • Johnson & Johnson
  • Mallinckrodt Medical
  • Novartis Pharmaceutical Corp.
  • Ovation Pharmaceuticals
  • Pfizer, Inc.
  • Roche
  • Shire
  • Solvay
  • Valeant Pharmaceuticals
• List Of Figures
  • Summary Table: Worldwide Sales Of Drugs Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 1 Dsm Classifications* Of Emotional And Behavioral Disorders
  • Table 2 Classification Of Emotional And Behavioral Disorders (As Done For This Report)
  • Table 3 Benzodiazepines
  • Table 4 Selective Serotonin Reuptake Inhibitors (SSRIS)
  • Table 5 Tricyclic Antidepressants
  • Table 6 Antihistamines
  • Table 7 Major Tranquilizers, Neuroleptics Or Antipsychotics
  • Table 8 Mood Stabilizers
  • Table 9 Cns Stmulants
  • Table 10 Nonstmulants
  • Table 11 Atypical Antipsychotics
  • Table 12 Drugs Used For Antianxiety Disorders
  • Table 13 Drugs Used For Severe Depression
  • Table 14 Drugs Used For Bipolar Disorder
  • Table 15 Drugs Used For Attention Deficit Hyperactivity Disorder
  • Table 16 Drugs Used For Autistic Disorder Treatment
  • Table 17 Drugs Used For Schizophrenia
  • Table 18 Labelled Use And Approved Age For Agents To Treat Behavioral And Emotional Disorders In Children And Adolescents
  • Table 19 Drugs Receiving A Boxed Warning, Other Product Labeling Changes, And A Medication Guide Pertaining To Pediatric Suicidal Tendencies
  • Table 20 Devices And Implants Approved By The Fda 2000-April 2005
  • Table 21 Market Shares Of Manufacturers Of Antianxiety Agents To Treat Behavior And Emotional Disorders, 2004 (%)
  • Table 22 Market Shares Of Manufacturers Of Antidepressant Agents To Treat Behavior And Emotional Disorders, 2004 (%)
  • Table 23 Market Shares Of Manufacturers Producing Drugs For Bipolar Disorder Treatment, 2004 (%)
  • Table 24 Market Shares Of Manufacturers Producing Adhd Drugs For Treating Behavior And Emotional Disorders, 2004 (%)
  • Table 25 Market Shares Of Manufacturers Of Autistic Disorder Drugs, 2004 (%)
  • Table 26 Market Shares Of Manufacturers Of Drugs For Treating Schizophrenia, 2004 (%)
  • Table 27 Market Shares Of Manufacturers Of Drugs For Treating Learning Disorders, 2004 (%)
  • Table 28 Market Shares Of Manufacturers Of Drugs For Treating Eating Disorders, 2004 (%)
  • Table 29 Market Shares Of Manufacturers Of Conduct Disorder Drugs, 2004 (%)
  • Table 30 Worldwide Sales Of Drugs By Type To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 31 Proportion Of Types Of Drugs Being Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2004
  • Table 32 Worldwide Sales Of Benzodiazepines Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 33 Worldwide Sales Of Selective Serotonin Reuptake Inhibitors Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 34 Worldwide Sales Of Tricyclic Antidepressants Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 35 Worldwide Sales Of Antihistamines Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 36 Worldwide Sales Of Major Tranqilizers, Neuroleptics Or Antipsychotics Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 37 Worldwide Sales Of Mood Stabilizers Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 38 Worldwide Sales Of Cns Stimulants Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 39 Worldwide Sales Of Nonstimulants Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 40 Worldwide Sales Of Atypical Antipsychotics Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 41 Worldwide Sales Of Drugs By Type Of Disorder To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 42 Percentage Share Of Global Market For Drugs Used To Treat Emotional And Behavioral Disorders In Children And Adolescents By Disorder Type, 2004 (%)
  • Table 43 Worldwide Sales Of Antianxiety Drugs Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 44 Worldwide Sales Of Antidepressants Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 45 Worldwide Sales Of Drugs To Treat Bipolar Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 46 Worldwide Sales Of Adhd Drugs Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 47 Worldwide Sales Of Autistic Disorder Drugs Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 48 Worldwide Sales Of Schizophrenia Drugs To Treat Emotional And Behavioral Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 49 Worldwide Sales Of Drugs Used To Treat Learning Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 50 Worldwide Sales Of Drugs Used To Treat Eating Disorders In Children And Adolescents, Through 2010
• ($ Millions)
  • Table 51 Worldwide Sales Of Drugs To Treat Conduct Disorders In Children And Adolescents, Through 2010
• ($ Millions)
  • Table 52 Demographics Of Antianxiety Drug Usage In Children And Adolescents, 2004 (%)
  • Table 53 Demographics For Antidepressant Drugs Usage In Children And Adolescents, 2004 (%)
  • Table 54 Demographics For Bipolar Disorder Drugs Usage In Children And Adolescents, 2004 (%)
  • Table 55 Demographics For Adhd Drugs Usage In Children And Adolescents, 2004 (%)
  • Table 56 Demographics For Autistic Disorder Drugs Usage In Children And Adolescents, 2004 (%)
  • Table 57 Demographics For Drugs Used To Treat Schizophrenia In Children And Adolescents, 2004 (%)
  • Table 58 Demographics For Learning Disorder Drugs In Children And Adolescents, 2004 (%)
  • Table 59 Demographics For Eating Disorder Drugs Usage In Children And Adolescents, 2004 (%)
  • Table 60 Demographics For Conduct Disorder Drugs Usage In Children And Adolescents, 2004 (%)
  • Table 61 New Drugs From Astrazeneca
  • Table 62 New Drugs From Bristol-Myers Squibb
  • Table 63 New Drugs From Celgene
  • Table 64 New Drugs From Glaxosmithkline
  • Table 65 New Drugs From Johnson & Johnson
  • Table 66 New Drugs From Merck
  • Table 67 New Drugs From Novartis
  • Table 68 New Drugs From Pfizer
  • Table 69 New Drugs From Roche
  • Table 70 New Drugs From Sanofi-Aventis
  • Table 71 New Drugs From Shire
  • Table 72 New Drugs From Solvay
  • Table 73 New Drugs From Wyeth
  • Table 74 Annual Number Of Patents Relating To Treatments For Emotional And Behavioral Disorders In Children And Adolescents, 2001-2005
  • Table 75 Total Number Of Patents Relating To Treatments For Emotional And Behavioral Disorders In Children And Adolescents By Category, 2001-2005
  • Table 76 Significant Patents For Drugs Used To Treat Behavioral And Emotional Disorders, 2005
  • Table 77 U.S. Patents Relating To Behavioral And Emotional Disorder Drugs By Company, 2001-2005
  • Table 78 U.S. Patents Relating To Behavioral And Emotional Disorder Drugs By Country, 2001-2005 (Number Of Patents)
  • Table 79 Trends Of Patents Relating To Behavioral And Emotional Disorder Drugs Issued By Country, 2005-2001
  • Table 80 Number And Share Of U.S. Patents Relating To Behavioral And Emotional Disorder Drugs By Assignee, 2001-2005
  • Table 81 Regional Sales Of Treatments For Behavioral And Emotional Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 82 Regional Sales Of Antianxiety Agents Used To Treat Behavioral And Emotional Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 83 Regional Sales Of Antidepressants Used To Treat Behavioral And Emotional Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 84 Regional Sales Of Bipolar Disorder Drugs Used To Treat Behavioral And Emotional Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 85 Regional Sales Of Adhd Drugs Used To Treat Behavioral And Emotional Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 86 Regional Sales Of Autistic Disorder Drugs To Treat Behavioral And Emotional Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 87 Regional Sales Of Drugs To Treat Schizophrenic Disorders In Children And Adolescents, Through 2010 ($ Millions)
  • Table 88 Regional Sales Of Learning Disorder Drugs To Treat Children And Adolescents, Through 2010 ($ Millions)
  • Table 89 Regional Sales Of Conduct Disorder Drugs Used To Treat Children And Adolescents, Through 2010 ($ Millions)
  • Table 90 Regional Sales Of Eating Disorder Drugs To Treat Children And Adolescents, Through 2010 ($ Millions)
• List Of Figures
  • Summary Figure: Worldwide Sales Of Drugs Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 1 Market Shares Of Manufacturers Of Antianxiety Agents To Treat Behavior And Emotional Disorders, 2004 (%)
  • Figure 2 Market Shares Of Manufacturers Of Antidepressant Agents To Treat Behavior And Emotional Disorders, 2004 (%)
  • Figure 3 Market Shares Of Manufacturers Producing Bipolar Disorder Drugs, 2004 (%)
  • Figure 4 Market Shares Of Manufacturers Of Adhd Drugs For Treating Behavior And Emotional Disorders, 2004 (%)
  • Figure 5 Market Shares Of Manufacturers Of Autistic Disorder Drugs, 2004 (%)
  • Figure 6 Market Shares Of Manufacturers Of Drugs For Treating Schizophrenia, 2004 (%)
  • Figure 7 Market Shares Of Manufacturers Of Drugs For Treating Learning Disorders, 2004 (%)
  • Figure 8 Market Shares Of Manufacturers Of Drugs To Treat Eating Disorders, 2004 (%)
  • Figure 9 Market Shares Of Manufacturers Of Conduct Disorder Drugs, 2004 (%)
  • Figure 10 Proportion Of Types Of Drugs Being Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2004 (%)
  • Figure 11 Worldwide Sales Of Benzodiazepines Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 12 Worldwide Sales Of Selective Serotonin Reuptake Inhibitors Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 13 Worldwide Sales Of Tricyclic Antidepressants Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 14 Worldwide Sales Of Antihistamines Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 15 Worldwide Sales Of Major Tranqilizers, Neuroleptics Or Antipsychotics Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 16 Worldwide Sales Of Mood Stabilizers Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 17 Worldwide Sales Of Cns Stimulants Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 18 Worldwide Sales Of Nonstimulants Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 19 Worldwide Sales Of Atypical Antipsychotics Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 20 Shares Of Global Market For Drugs Used To Treat Emotional And Behavioral Disorders In Children And Adolescents By Disorder Type, 2004 (%)
  • Figure 21 Worldwide Sales Of Antianxiety Drugs Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 22 Worldwide Sales Of Antidepressants Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 23 Worldwide Sales Of Drugs To Treat Bipolar Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 24 Worldwide Sales Of Adhd Drugs Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 25 Worldwide Sales Of Autistic Disorder Drugs Used To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 26 Worldwide Sales Of Schizophrenia Drugs To Treat Emotional And Behavioral Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 27 Worldwide Sales Of Drugs Used To Treat Learning Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 28 Worldwide Sales Of Drugs Used To Treat Eating Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 29 Worldwide Sales Of Drugs To Treat Conduct Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 30 Demographics Of Antianxiety Drug Usage In Children And Adolescents, 2004 (%)
  • Figure 31 Demographics For Antidepressant Drugs Usage In Children And Adolescents, 2004 (%)
  • Figure 32 Demographics For Bipolar Disorder Drugs Usage In Children And Adolescents, 2004 (%)
  • Figure 33 Demographics For Adhd Drugs Usage In Children And Adolescents, 2004 (%)
  • Figure 34 Demographics For Autistic Disorder Drugs Usage In Children And Adolescents, 2004 (%)
  • Figure 35 Demographics For Drugs Used To Treat Schizophrenia In Children And Adolescents, 2004 (%)
  • Figure 36 Demographics For Learning Disorder Drugs In Children And Adolescents, 2004 (%)
  • Figure 37 Demographics For Eating Disorder Drugs Usage In Children And Adolescents, 2004 (%)
  • Figure 38 Demographics For Conduct Disorder Drugs Usage In Children And Adolescents, 2004 (%)
  • Figure 39 Total Patents For Emotional And Behavioral Disorder Treatments In Children And Adolescents, 2001-2005
  • Figure 40 Annual Share Of Patents For Emotional And Behavioral Disorder Treatments In Children And Adolescents, 2001-2005 (%)
  • Figure 41 Total Number Of Patents Relating To Treatments For Emotional And Behavioral Disorders In Children And Adolescents By Category, 2001-2005
  • Figure 42 Share Of Total Number Of Patents Relating To Treatments For Emotional And Behavioral Disorders In Children And Adolescents By Category, 2001-2005 (%)
  • Figure 43 U.S. Patents Relating To Behavioral And Emotional Disorder Drugs By Country, 2001-2005 (Number Of Patents)
  • Figure 44 Trends Of Patents Relating To Behavioral And Emotional Disorder Drugs Issued By Country, 2001-2005
  • Figure 45 Share Of Patents Relating To Behavioral And Emotional Disorder Drugs Issued By Country, 2001-2005 (%)
  • Figure 46 Number Of U.S. Patents Relating To Behavioral And Emotional Disorder Drugs By Assignee, 2001-2005 (Number Of Patents)
  • Figure 47 Shares Of U.S. Patents Relating To Behavioral And Emotional Disorder Drugs By Assignee, 2001-2005 (%)
  • Figure 48 Regional Sales Of Antianxiety Agents Used To Treat Behavioral And Emotional Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 49 Regional Sales Of Antidepressants Used To Treat Behavioral And Emotional Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 50 Regional Sales Of Bipolar Disorder Drugs Used To Treat Behavioral And Emotional Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 51 Regional Sales Of Adhd Drugs Used To Treat Behavioral And Emotional Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 52 Regional Sales Of Adhd Drugs To Treat Behavioral And Emotional Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 53 Regional Sales Of Drugs To Treat Schizophrenic Disorders In Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 54 Regional Sales Of Learning Disorder Drugs To Treat Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 55 Regional Sales Of Conduct Disorder Drugs Used To Treat Children And Adolescents, 2003-2010 ($ Millions)
  • Figure 56 Regional Sales Of Eating Disorder Drugs To Treat Children And Adolescents, 2003-2010 ($ Millions)